Payers, Pharma Need “Talk Therapy” In Drug Pricing Dispute – Former Highmark CEO
This article was originally published in The Pink Sheet Daily
Insurance experts discuss working with the pharmaceutical industry on solutions to paying for high-cost drugs, including risk sharing arrangements, at the FDA/CMS Summit for Payers.
You may also be interested in...
Bipartisan congressional letters seek relief from HHS but the Trump Administration has taken aim at 340B providers itself and may not be inclined to help.
Value-based contracting in the US is moving toward high-cost drugs for rare disease and away from lower cost chronic treatments as payers plan for the coming pipeline of cell and gene therapies. Marketed gene therapies all have some kind of risk sharing deal in place but further progress on the most innovative payment models is hampered by regulatory and operational challenges. The Centers for Medicare and Medicaid Services has taken a first step toward addressing regulatory obstacles but there is a long way to go.
Results of an analysis published in JAMA could undercut arguments against legislative proposals establishing inflation penalties in Medicare.